Lila Sciences

About
What does Lila Sciences do?
Lila Sciences, founded in 2023 by Geoffrey von Maltzahn (Flagship Pioneering), uses AI to fully automate the scientific method. Emerged March 2025 with $200M seed, closed $350M Series A for $550M total at >$1.3B valuation (Oct 2025).
What is Lila Sciences's revenue?
StartupHub estimates Lila Sciences's annual revenue at $531.3M (range $259.1M to $1.2B, 45% confidence), based on comparable companies in the sector.
What is Lila Sciences's valuation?
StartupHub estimates Lila Sciences's effective valuation at $7.8B (range $5.5B to $10.1B, 43% confidence), based on comparable companies in the sector.
How much funding has Lila Sciences raised?
Lila Sciences has raised a total of $2.2B in funding. The most recent round on record is Funding Round.
Where is Lila Sciences headquartered?
Lila Sciences is headquartered in Cambridge, United States.
When was Lila Sciences founded?
Lila Sciences was founded in 2023.
What industry does Lila Sciences operate in?
Lila Sciences operates in Artificial Intelligence, Biotechnology, Lab Automation, Scientific Research, AI Discovery, NeoLab.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.

